These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 31344332)

  • 61. Statins plus ezetimibe in the era of proprotein convertase subtilisin/ kexin type 9 inhibitors.
    De Luca L; Corsini A; Uguccioni M; Colivicchi F
    Kardiol Pol; 2020 Sep; 78(9):850-860. PubMed ID: 32716152
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Inhibitors of PCSK9].
    Petrova-Slater I; Denegri A; Pasotti E; Rossi MG; Spirk D; Riesen WF; Moccetti T; Moccetti M
    Rev Med Suisse; 2017 Apr; 13(558):821-825. PubMed ID: 28727332
    [TBL] [Abstract][Full Text] [Related]  

  • 63. What is new in lipid-lowering therapies in diabetes?
    Cheung YM; O'Brien R; Ekinci EI
    Intern Med J; 2019 Dec; 49(12):1472-1480. PubMed ID: 30887650
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Intensive LDL-cholesterol lowering therapy and neurocognitive function.
    Banach M; Rizzo M; Nikolic D; Howard G; Howard V; Mikhailidis D
    Pharmacol Ther; 2017 Feb; 170():181-191. PubMed ID: 27865998
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
    Achimastos A; Alexandrides T; Alexopoulos D; Athyros V; Bargiota A; Bilianou E; Chrysochoou C; Drogari E; Elisaf M; Ganotakis E; Goudevenos I; Ioannidis I; Kolovou G; Kotsis V; Lekakis I; Liberopoulos E; Melidonis A; Nikolaou V; Ntaios G; Papanas N; Pappas S; Pitsavos C; Rallidis L; Richter D; Skoumas I; Tentolouris N; Tousoulis D; Tselepis A; Tsioufis K; Tziakas D; Tziomalos K; Vardas P; Vlachopoulos C; Vlahakos D
    Hormones (Athens); 2016; 15(1):8-14. PubMed ID: 27086681
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
    Stroes E; Guyton JR; Lepor N; Civeira F; Gaudet D; Watts GF; Baccara-Dinet MT; Lecorps G; Manvelian G; Farnier M;
    J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27625344
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Lipid management in patients with chronic kidney disease.
    Ferro CJ; Mark PB; Kanbay M; Sarafidis P; Heine GH; Rossignol P; Massy ZA; Mallamaci F; Valdivielso JM; Malyszko J; Verhaar MC; Ekart R; Vanholder R; London G; Ortiz A; Zoccali C
    Nat Rev Nephrol; 2018 Dec; 14(12):727-749. PubMed ID: 30361677
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.
    Toth PP; Dwyer JP; Cannon CP; Colhoun HM; Rader DJ; Upadhyay A; Louie MJ; Koren A; Letierce A; Mandel J; Banach M
    Kidney Int; 2018 Jun; 93(6):1397-1408. PubMed ID: 29526502
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Lipid management to mitigate poorer postkidney transplant outcomes.
    Skulratanasak P; Larpparisuth N
    Curr Opin Nephrol Hypertens; 2023 Jan; 32(1):27-34. PubMed ID: 36250471
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances.
    Atar D; Langslet G; Tonstad S
    Kardiol Pol; 2022; 80(7-8):741-749. PubMed ID: 35521719
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels.
    Abujrad H; Mayne J; Ruzicka M; Cousins M; Raymond A; Cheesman J; Taljaard M; Sorisky A; Burns K; Ooi TC
    Atherosclerosis; 2014 Mar; 233(1):123-9. PubMed ID: 24529132
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
    Wójcik C
    Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Kidney and lipids: novel potential therapeutic targets for dyslipidemia in kidney disease?
    Zuzda K; Grycuk W; Małyszko J; Małyszko J
    Expert Opin Ther Targets; 2022 Nov; 26(11):995-1009. PubMed ID: 36548906
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia.
    Cicero AFG; Bove M; Borghi C
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):9-15. PubMed ID: 29231064
    [TBL] [Abstract][Full Text] [Related]  

  • 75. What is the impact of the 2017 cochrane systematic review and meta-analysis that evaluated the use of PCSK9 inhibitors for lowering cardiovascular disease and mortality?
    Jalloh MA; Doroudgar S; Ip EJ
    Expert Opin Pharmacother; 2018 May; 19(7):739-741. PubMed ID: 29667439
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors.
    Shahreyar M; Salem SA; Nayyar M; George LK; Garg N; Koshy SKG
    J Am Board Fam Med; 2018; 31(4):628-634. PubMed ID: 29986989
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Gender Disparities in Health Resource Utilization in Patients with Atherosclerotic Cardiovascular Disease: A Retrospective Cross-Sectional Study.
    Shen X; DiMario S; Philip K
    Adv Ther; 2019 Dec; 36(12):3424-3434. PubMed ID: 31625131
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Therapy for Hyperlipidemia.
    Wright J; Subramanian S
    Med Clin North Am; 2024 Sep; 108(5):881-894. PubMed ID: 39084839
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias.
    Packard CJ
    Curr Cardiol Rep; 2018 Jun; 20(8):60. PubMed ID: 29904807
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Statin combination therapy and cardiovascular risk reduction.
    Toth PP; Farnier M; Tomassini JE; Foody JM; Tershakovec AM
    Future Cardiol; 2016 May; 12(3):289-315. PubMed ID: 27079178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.